Answers are grounded in this paper and cite their sources.
Short-chain fatty acids are principal metabolites generated by gut microbiota during dietary fiber fermentation. They play essential roles in preserving intestinal barrier integrity and maintaining host immune homeostasis. Graves’ disease and its principal ocular complication, thyroid eye disease, are closely related autoimmune thyroid disorders. Together they impose a substantial burden on patient health and quality of life, presenting an important clinical challenge. Recent evidence indicates that reduced levels of these bacterial metabolites, particularly butyrate, are closely linked to the onset and progression of both conditions. This review summarizes current evidence on how changes in gut microbiota-derived metabolites contribute to these two disorders. In Graves’ disease, reduced production of short-chain fatty acids is associated with systemic immune dysregulation. These metabolites restore the balance between pro-inflammatory T helper 17 cells and regulatory T cells, suppress autoantibody generation by B lymphocytes, and preserve intestinal barrier integrity. In thyroid eye disease, beyond these systemic immune benefits, short-chain fatty acids—especially butyrate—can act directly on orbital fibroblasts to inhibit local inflammation, fibrosis, and fat accumulation, thereby slowing pathological tissue remodeling behind the eye. Therapeutic strategies aimed at modulating gut microbiota or directly supplementing short-chain fatty acids may offer novel promising approaches for managing Graves’ disease and its associated eye disease.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: